Frankincense (Boswellia sacra)
Frankincense (Boswellia sacra) contains boswellic acids, particularly acetyl-11-keto-β-boswellic acid (AKBA), which inhibit 5-lipoxygenase (5-LOX) to reduce leukotriene synthesis and dampen inflammatory cascades. Most supporting evidence derives from in vitro and animal models, with limited but promising human clinical data for inflammatory conditions.
Origin & History
Frankincense is the aromatic resin derived from the tree Boswellia sacra, native to Oman and the Arabian Peninsula. It is extracted through incisions made in the bark of the tree, producing a resin composed of essential oil, gum, and a lipophilic fraction.
Historical & Cultural Context
Frankincense has been traditionally used in Middle Eastern medicine, especially in Oman, for treating various ailments. It is also highly valued in the commercial production of cosmetics, food flavors, and perfumes.
Health Benefits
• Potential antimicrobial and antioxidant properties from in vitro studies, though human data is lacking. • Boswellic acids may inhibit 5-lipoxygenase, suggesting anti-inflammatory potential, based on chemical studies. • Historical use in Middle Eastern traditional medicine for various ailments. • Utilized in cosmetics and perfumes for its aromatic properties. • Preliminary studies highlight boswellic acids' potential benefits, but human trials are needed.
How It Works
Acetyl-11-keto-β-boswellic acid (AKBA) selectively inhibits 5-lipoxygenase (5-LOX), blocking the conversion of arachidonic acid into pro-inflammatory leukotrienes such as LTB4. Boswellic acids also suppress NF-κB activation, reducing downstream transcription of cytokines including TNF-α and IL-1β. Additionally, AKBA has been shown to inhibit human leukocyte elastase (HLE), potentially contributing to its anti-inflammatory and tissue-protective effects.
Scientific Research
There is a lack of specific human clinical trials, RCTs, or meta-analyses for Boswellia sacra frankincense. The research primarily consists of in vitro studies focusing on chemical composition and potential properties.
Clinical Summary
Most human evidence for Boswellia sacra specifically is sparse; the bulk of clinical trials use Boswellia serrata extracts standardized to AKBA. A small randomized trial in osteoarthritis patients (n=30) using a Boswellia extract reported a statistically significant reduction in pain scores and improved mobility over 8 weeks compared to placebo. In vitro studies consistently demonstrate 5-LOX inhibition at micromolar AKBA concentrations, though translation to human therapeutic outcomes remains incompletely established. Overall, the evidence base is preliminary and larger, well-controlled trials specific to Boswellia sacra are needed before firm efficacy conclusions can be drawn.
Nutritional Profile
Frankincense (Boswellia sacra) resin is not consumed as a conventional food ingredient and thus lacks a standard nutritional profile in terms of macronutrients. However, its chemical composition is well-characterized: Primary bioactive compounds are pentacyclic triterpenic boswellic acids, comprising approximately 25–35% of the resin by dry weight, with key constituents including β-boswellic acid, acetyl-β-boswellic acid (AβBA), 11-keto-β-boswellic acid (KBA), and acetyl-11-keto-β-boswellic acid (AKBA), the latter present at roughly 1–5% and considered most pharmacologically potent. The essential oil fraction constitutes approximately 5–9% of the resin and contains monoterpenes (α-pinene ~40–60% of oil fraction, limonene ~3–8%, p-cymene ~2–5%), sesquiterpenes (incensole acetate ~2–10%), and diterpenes. Polysaccharides (arabinogalactans) make up approximately 15–20% of the resin. Macro- and micronutrient content (carbohydrates, proteins, fats, vitamins, minerals) is negligible given that frankincense is used in trace aromatic or supplemental doses, not as a dietary staple. Bioavailability of boswellic acids is limited by poor oral absorption; lipophilic delivery formulations (e.g., with lecithin) have been shown in studies to increase plasma AKBA levels by up to 5-fold compared to standard extracts. Typical oral supplement doses studied range from 300–1200 mg of standardized extract daily.
Preparation & Dosage
No clinically studied dosage ranges for Boswellia sacra are specified, as human clinical data is absent. Consult a healthcare provider before starting any new supplement.
Synergy & Pairings
Turmeric, Black Pepper, Ginger, Ashwagandha, Ginkgo Biloba
Safety & Interactions
Boswellia sacra is generally well tolerated at typical doses (300–500 mg extract daily), with the most commonly reported adverse effects being mild gastrointestinal upset, nausea, and diarrhea. Due to its anti-inflammatory mechanism involving arachidonic acid pathways, concurrent use with NSAIDs or anticoagulants such as warfarin warrants caution, as additive effects on bleeding risk are theoretically possible. Pregnant and breastfeeding women should avoid use, as some animal data suggest uterine-stimulating activity and safety in human pregnancy has not been established. Individuals with liver conditions should consult a physician before use, as rare cases of hepatotoxicity have been reported with concentrated Boswellia preparations.